Sensitivity and specificity of Briganti nomogram in Turkish patients undergoing radical prostatectomy and pelvic lymph node dissection

Sahin A., Urkmez A., Yildirim C., Ali Kutluhan M., Topaktaş R., Verit A.

Aging Male, cilt.23, sa.5, ss.836-840, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1080/13685538.2019.1601176
  • Dergi Adı: Aging Male
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Abstracts in Social Gerontology, AgeLine, CINAHL, EMBASE, MEDLINE, SportDiscus
  • Sayfa Sayıları: ss.836-840
  • Anahtar Kelimeler: Briganti nomogram, invasion, pelvic lymph node, prostate cancer, radical prostatectomy
  • Bilecik Şeyh Edebali Üniversitesi Adresli: Hayır

Özet

Aim: To investigate the accuracy of Briganti nomogram in patients who underwent Pelvic lymph node dissection (PLND). Methods: Hundred and sixty-five patients who underwent radical prostatectomy and PLND between 2012 and 2018 in our clinics were included, and their data were retrospectively screened. Results: The mean age of patients was 63.6 ± 5.8 (range: 49–76) years. Hundred and thirty-five (81.8%) patients had a Briganti score of <5, whereas 30 (18.2%) had a Briganti score of ≥5. The preoperative T-PSA levels, biopsy grades and the incidence of T2b and T2c stages in patients with a Briganti score of ≥5 was significantly higher than that in patients with a Briganti score of <5 (p: .026; p: .000; p: .001, respectively). The incidence of lymph node positivity in patients with a Briganti score of ≥5 (76.7%) was significantly higher than that in patients with a Briganti score of <5 (25.2%) (p: .000). The sensitivity of the Briganti score to detect lymph node positivity was 40.35%, specificity was 93.52%, positive predictive value was 76.67% and the negative predictive value was 74.81%. The accuracy of the test was 75.15%. Conclusion: Nomograms provide useful information regarding prostate cancer. Risk estimates should be carefully considered, and treatment decisions should be given with a patient-specific approach.